Retatrutide for PCOS: Triple GLP-1/GIP/Glucagon Agonist — 2026 Update

What Is Retatrutide?

Retatrutide (development code LY3437943) is a drug candidate developed by Eli Lilly belonging to a new therapeutic class: triple agonists of the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Like semaglutide and tirzepatide, it is administered as a once-weekly subcutaneous injection.

To understand its novelty, compare it to existing approved agents:

• Semaglutide (Ozempic / Wegovy) — GLP-1 receptor agonist only
• Tirzepatide (Mounjaro / Zepbound) — dual GLP-1 + GIP agonist
• Retatrutide — triple GLP-1 + GIP + glucagon agonist

The addition of glucagon receptor agonism is the key differentiator. While glucagon is classically associated with raising blood sugar (counter-regulatory response to hypoglycemia), its activation at controlled sub-physiological doses produces a different metabolic effect: increased lipolysis and elevated basal energy expenditure — without causing hyperglycemia, because the GLP-1 and GIP components maintain insulin secretion as a counterbalance.

Retatrutide is currently in Phase 3 clinical trials (ACHIEVE-1 and ACHIEVE-2, both launched in 2024). No regulatory approval has yet been obtained from the FDA or EMA.

Why Add Glucagon to the Equation?

The rationale behind glucagon receptor agonism in a weight-loss drug is both elegant and counterintuitive. Glucagon is normally the hyperglycemic hormone — secreted by pancreatic alpha cells in response to low blood sugar. Why activate it in an anti-obesity treatment?

The answer lies in glucagon's extrapancreatic metabolic effects:

• Increased basal energy expenditure: glucagon receptors on brown adipose tissue and in the liver, when activated at controlled doses, increase thermogenesis and resting metabolic rate by an estimated 15–20% more than GLP-1 alone.
• Stimulated lipolysis: activation of hormone-sensitive lipase in adipose tissue drives mobilization of free fatty acids as an energy substrate, amplifying fat mass loss.
• Direct hepatic action: reduction of de novo lipogenesis and hepatic triglyceride synthesis — potentially beneficial in NAFLD/NASH (non-alcoholic fatty liver disease), which is common in PCOS.
• Preserved glycemic control: the GLP-1 and GIP components stimulate glucose-dependent insulin secretion, fully compensating for glucagon's potential hyperglycemic effect. The net result: no hyperglycemia, but greater energy expenditure.

This synergistic triple mechanism explains why retatrutide produces greater weight loss than dual agonists, without worsening cardiovascular or glycemic safety signals in available Phase 2 data.

Phase 2 Data: The Results

The pivotal Phase 2 study, published by Jastreboff et al. in the NEJM in 2023 (volume 389, pages 514–526), is the primary reference for retatrutide in obesity:

Results at the optimal 12 mg dose:

• Mean body weight reduction: -24.2% (approximately -26.4 kg average)
• 58% of participants lost ≥ 20% of body weight
• Significant reductions in fasting glucose, HOMA-IR, and triglycerides
• Improved systolic blood pressure (-5 mmHg average)
• Discontinuation rate due to adverse events: 7% (primarily nausea)

Indirect comparison (separate trials, no head-to-head):

Side effects: the profile mirrors other GLP-1 agents — nausea (40%), vomiting (20%), diarrhea (15%), primarily during titration. No new safety signals for pancreatitis, thyroid C-cell tumors, or major cardiovascular events appeared in Phase 2. Phase 3 data (n ~ 3,000) will be needed to confirm the safety profile at scale.

Implications for People with PCOS

No PCOS-specific clinical trial has been published for retatrutide. The following implications are inferred from the mechanism of action and Phase 2 data:

Insulin resistance: if weight loss is greater than tirzepatide (-24% vs -22%), improvement in HOMA-IR should be at least equivalent — Phase 2 data show a significant HOMA-IR reduction at 12 mg. In PCOS, each 10% reduction in body weight is associated with meaningful improvements in insulin resistance and menstrual cycle regularity.

Hyperandrogenism: in PCOS, weight loss and IR improvement reduce ovarian androgen production (LH-driven testosterone). Retatrutide's effects on the androgenic axis in PCOS are inferrable but not yet directly demonstrated.

NAFLD/fatty liver: NAFLD is present in 30–40% of people with PCOS. The direct hepatic action of retatrutide via glucagon agonism (reduction of de novo lipogenesis) could be a specific advantage in this subgroup. Eli Lilly's Phase 2 NAFLD/NASH trial has completed (results 2025), and positive data are expected.

Fertility and pregnancy: no fertility, ovulation, or pregnancy data are available from Phase 2. As with all GLP-1 agents, discontinuation before conception is recommended. The indirect effect via weight loss on ovulation restoration is probable but not yet quantified for retatrutide.

Important caveat: the inferences above do not substitute for PCOS-specific clinical evidence. Phase 3 trials are expected to include subgroup analyses for participants with PCOS and obesity.

Where Does Clinical Development Stand?

Retatrutide's clinical development program includes several parallel trials:

Estimated regulatory timeline: if Phase 3 results confirm Phase 2 data, an NDA submission to the FDA is expected in 2026-2027. FDA approval could come in 2027 under standard review — potentially earlier with priority review or accelerated approval if liver disease data are strong. EMA submission would follow a similar timeline for European access.

Should You Wait for Retatrutide Before Starting GLP-1 Treatment?

This is the practical question many people with PCOS ask after reading about retatrutide. The pragmatic answer is: no, in the vast majority of cases.

If your need is urgent (documented IR, very irregular cycles, fertility goals within 1–2 years, weight affecting health): semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are available today, with demonstrated benefits in PCOS-relevant populations. Waiting 2–3 years for an unapproved drug foregoes potential benefit now.

If your fertility timeline is > 2 years and your PCOS is stable: it may be reasonable to monitor Phase 3 publication (expected late 2025 – early 2026) before committing to a long-term GLP-1 strategy. If retatrutide confirms its Phase 2 superiority, it could become the preferred agent for PCOS with obesity and severe IR.

Reminder: pharmacological treatment for PCOS is always combined with lifestyle modifications (diet, physical activity). These interventions remain effective independently of which drug is chosen.

Expected Pricing and US Access

Eli Lilly has not yet officially communicated pricing for retatrutide. Market estimates, based on premium positioning versus tirzepatide, project:

• US list price: approximately $1,500–$2,000/month, compared to ~$1,000/month for Zepbound (tirzepatide 15 mg) and ~$1,300/month for Wegovy (semaglutide 2.4 mg)
• With insurance: copay programs (Eli Lilly typically offers savings cards) often reduce out-of-pocket to $25–$150/month for commercially insured patients
• Medicare/Medicaid: GLP-1 agents for obesity are increasingly covered following the 2024 proposed CMS rule, though final coverage for retatrutide would depend on FDA approval and formulary decisions

FSA/HSA eligibility is expected, as with other approved GLP-1 agents, once FDA approval is granted.

For people with PCOS specifically, insurance coverage for GLP-1 agents typically requires a documented obesity diagnosis (BMI ≥ 30, or ≥ 27 with comorbidity) rather than a PCOS diagnosis alone. This is the current access pathway for semaglutide and tirzepatide, and would likely apply to retatrutide as well.

Frequently Asked Questions

Sources

• Jastreboff AM et al. — Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Obesity. NEJM 2023;389:514–526.
• Eli Lilly — Pipeline & Development Programs, Retatrutide (LY3437943), 2025.
• ClinicalTrials.gov — NCT05584774 (ACHIEVE-1); NCT05902429 (ACHIEVE-2).
• ESHRE — International Evidence-Based Guidelines for PCOS Assessment and Management (2023).
• ESHRE — Workshop on emerging therapies in PCOS (2024).